YM BioSciences

YM BioSciences is a biotech company towards finding cancer cures. Its recent work includes EGF receptor monoclonal antibody called TheraCIM hR3, which has been given orphan status by the Food and Drug Administration (FDA). It is targeted to treatment of gliomas. TheraCIM hR3, nimotuzumab, is currently undergoing two Phase II trials in Europe and is expected to become a Phase III candidate in early 2005.

External link

 * Official site